top of page

OLCIAS · CONFERENCE ARCHIVE

NeuroPharma & Brain Therapeutics — Conference archive

Explore previous OLCIAS conference material, revisit presentations, and connect with the next scientific conversation.

Watch recordings and stay connected

Watch past conferences on OLCIAS YouTube →

Follow the OLCIAS LinkedIn company page & explore recordings →

Connect with the OLCIAS LinkedIn profile →

Past programmes and research

Past scientific programme →

Past conference discussion group →

Published abstracts →

Continue the conversation in 2027

NeuroPharma & Brain Therapeutics now continues within Neuroscience & NeuroTech 2027 →.

9 January 2027 · 8:30 PM IST · Live online

Explore all six OLCIAS conferences for 2027 →

This is an archive. Historical dates, speakers and presentations refer to previous editions. Recording availability varies by event.

  • Emerging Technologies in Drug Discovery: AI and Machine Learning

  • Novel Approaches in Drug Design and Discovery

  • Therapeutic Strategies for Brain and Mental Disorders: New Discoveries and Current Challenges

  • Preclinical Development and Clinical Trials: Lessons Learned and Best Practices

  • Drug Delivery and Formulation: Novel Approaches to Enhance Efficacy and Safety

  • Innovations in Precision Medicine: Opportunities and Challenges in Personalized Drug Discovery

  • Regulatory and Ethical Considerations in Drug Discovery and Development

  • Investor and Industry Perspectives on Drug Discovery: Opportunities and Challenges

  • The Future of Drug Discovery: Perspectives and Prospects
     

Our conference will feature a range of sessions, including presentations, posters, and interactive discussions, that will provide attendees with opportunities to engage with the latest research and advances in drug discovery. By participating in this conference, we hope to facilitate collaborations and inspire new ideas that will lead to better diagnosis, treatment, and care for individuals with brain and mental problems.

  1. The National Institute of Mental Health (NIMH) spent approximately $1.9 billion on research related to mental health in 2020, which includes funding for drug discovery and development. You can find more information on NIMH funding at: https://report.nih.gov/categorical_spending.aspx

  2. According to a report by the Pharmaceutical Research and Manufacturers of America (PhRMA), member companies spent $83 billion on research and development in 2019, including investments in treatments for neurological and psychiatric disorders. You can find more information on PhRMA's annual report at: https://www.phrma.org/annual-report

  3. The World Health Organization (WHO) estimates that the global economic burden of mental illness is $2.5 trillion per year, which includes the costs of healthcare, lost productivity, and other indirect costs. You can find more information on WHO's data on global health expenditures at: https://www.who.int/data/gho/data/themes/health-expenditure.

  4. The National Institutes of Health (NIH) provides data on the funding for research related to neurological and psychiatric disorders, including drug discovery and development. In 2020, the NIH spent approximately $1.8 billion on research related to neuroscience and behavior. You can find more information on NIH funding at: https://report.nih.gov/categorical_spending.aspx.

  5. The National Alliance on Mental Illness (NAMI) estimates that the total economic cost of untreated mental illness in the United States is over $300 billion per year, which includes healthcare costs, lost productivity, and other indirect costs. You can find more information on NAMI's data on mental health spending at: https://www.nami.org/About-NAMI/Publications-Reports/Public-Policy-Reports/The-Economic-Burdens-of-Excessively-Low-Wages-for-Direct-Support-Professionals.

Title: The International Live Conference on Drug Discovery
Date: March 16, 2024
​Time: 8 PM Indian Standard Time
Location: Online
Conference Theme: 
Innovating the Future of Drug Discovery: Emerging Technologies and Novel Approaches

Title: International Live Conference on Drug Discovery for Brain Health, Mental Well-being, and Neurological Disorders

Date: March 29, 2025

Time: 8:00 PM Indian Standard Time

Location: Online

Conference Theme: Innovating the Future of Drug Discovery through Emerging Technologies and Novel Approaches

 

 

In addition to the primary theme, a dedicated special track will focus on brain and mental disorders. This track provides a unique platform for researchers and experts to share and discuss their recent findings in neuroscience, covering new drug discoveries, emerging therapies, and their potential applications in treating mental health disorders. The special track aims to delve into the challenges and opportunities in drug discovery for brain and mental disorders, fostering collaboration between researchers and industry professionals. We anticipate an engaging and enlightening conference that will positively impact global drug discovery research.

 

Conference Sessions:

 

1. Emerging Technologies in Drug Discovery: AI and Machine Learning

2. Novel Approaches in Drug Design and Discovery

3. Therapeutic Strategies for Brain and Mental Disorders: New Discoveries and Current Challenges

4. Preclinical Development and Clinical Trials: Lessons Learned and Best Practices

5. Drug Delivery and Formulation: Novel Approaches to Enhance Efficacy and Safety

6. Innovations in Precision Medicine: Opportunities and Challenges in Personalized Drug Discovery

7. Regulatory and Ethical Considerations in Drug Discovery and Development

8. Investor and Industry Perspectives on Drug Discovery: Opportunities and Challenges

9. The Future of Drug Discovery: Perspectives and Prospects

 

The conference will feature various sessions, including presentations, posters, and interactive discussions, providing attendees with opportunities to engage with the latest research and advances in drug discovery. Our goal is to facilitate collaborations and inspire new ideas that contribute to improved diagnosis, treatment, and care for individuals with brain and mental health issues.

 

 

Event Highlights:

 

2. YouTube Recording: Can't make it live? Don't worry! All sessions will be recorded and available on our YouTube channel for later viewing.

 

 

We eagerly anticipate your active participation and engagement in this groundbreaking event! If you have any questions, feel free to email us at conferences@olcias.com.
 

Publicly Available Financial Data on Drug Discovery and Development for Brain and Mental Disorders

  1. The National Institute of Mental Health (NIMH) spent approximately $1.9 billion on research related to mental health in 2020, which includes funding for drug discovery and development. You can find more information on NIMH funding at: https://report.nih.gov/categorical_spending.aspx

  2. According to a report by the Pharmaceutical Research and Manufacturers of America (PhRMA), member companies spent $83 billion on research and development in 2019, including investments in treatments for neurological and psychiatric disorders. You can find more information on PhRMA's annual report at: https://www.phrma.org/annual-report

  3. The World Health Organization (WHO) estimates that the global economic burden of mental illness is $2.5 trillion per year, which includes the costs of healthcare, lost productivity, and other indirect costs. You can find more information on WHO's data on global health expenditures at: https://www.who.int/data/gho/data/themes/health-expenditure.

  4. The National Institutes of Health (NIH) provides data on the funding for research related to neurological and psychiatric disorders, including drug discovery and development. In 2020, the NIH spent approximately $1.8 billion on research related to neuroscience and behavior. You can find more information on NIH funding at: https://report.nih.gov/categorical_spending.aspx.

  5. The National Alliance on Mental Illness (NAMI) estimates that the total economic cost of untreated mental illness in the United States is over $300 billion per year, which includes healthcare costs, lost productivity, and other indirect costs. You can find more information on NAMI's data on mental health spending at: https://www.nami.org/About-NAMI/Publications-Reports/Public-Policy-Reports/The-Economic-Burdens-of-Excessively-Low-Wages-for-Direct-Support-Professionals.

NeuroPharma 2025.png
bottom of page